ClinicalTrials.Veeva

Menu

Paracetamol Vs Caffeine Vs Codeine in the Management of Post Traumatic Pain in Emergencies

U

University of Monastir

Status and phase

Completed
Phase 3

Conditions

Acute Pain Due to Trauma

Treatments

Drug: Paracetamol caféine
Drug: Paracetamol
Drug: Paracetamol Codeine

Study type

Interventional

Funder types

Other

Identifiers

NCT05229965
Codeine-Cafeine-Paracetamol

Details and patient eligibility

About

The purpose of this study is to:

Compare the effect of paracetamol alone against Paracetamol+Codeine association against the association of paracetamol + Cafeine in the treatment of post-traumatic acute pain of the limbs.

Full description

At admission to the emergency department, patients with acute post-traumatic pain will be included, regardless of their initial NRS .These patients will receive the necessary care for their injury (icing, reduction, immobilization, local care, sutures), then went home with a medical prescription and an outpatient appointment .

At discharge and after obtaining their signed consent . All patients included will be randomized according to a numerical randomization table ( assigned in a 1:1:1 ratio) into 3 groups ( As a treatment for their post traumatic pain at discharge for 7 days ) :

  • Group 1: Paracetamol group who will receive paracetamol ( 1000 mg) : one pill 3 times a day for 7 days .
  • Group 2: Paracetamol-codeine group who will receive an association of 500 mg of Paracetamol and 30 mg of codeine : one pill twice a day for 7 days .
  • Group 3: Paracetamol-cafeine group who will receive an association of 500 mg of Paracetamol and 65 mg of cafeine : one pill 3 times a day for 7 days .

For all patients included in the study, demographic and clinical data will be collected by the physician or investigator and recorded on a pre-established form.

The demographic data recorded on each patient's chart were as follows: Age, sex, origin and personal pathological history:

  • Hypertension.
  • Diabetes.
  • Respiratory insufficiency.
  • Renal insufficiency.
  • Liver failure.
  • Allergy.

And a Clinical examination data:

  • Pain intensity (NRS).
  • Mechanism of trauma and site of injury.
  • Other physical examination data: systolic blood pressure (SBP), heart rate (HR) and temperature.
  • Nature of traumatic injury.
  • Final diagnosis
  • Injury Severity Score (ISS).
  • NRS at discharge (at rest and on movement).

Patients included will be assessed at Day 1 , Day 2 , Day 3 and Day 7 after discharge from the emergency department by a telephone call. This evaluation will include :

  • NRS at rest and during movement

  • Secondary use of another analgesic.

  • Patient satisfaction assessed by Likert scale, with 3 responses:

    • Satisfied
    • Moderately satisfied
    • Not satisfied
  • Side effects: epigastralgia, dizziness, somnolence, headache, nausea and/or vomiting, insomnia, constipation, palpitation, etc.

Enrollment

1,500 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age :18 years or older
  • Patients presented to the emergency department with acute post-traumatic pain and residual pain at rest and/or on movement with a numerical pain rating scale (NRS) > 3/10 on discharge.
  • They all signed a written consent form.

Exclusion criteria

  • Self-mutilation
  • Severe acute trauma that may require hospitalization
  • Open or complicated fracture requiring surgical management
  • Regular use of analgesics
  • Any known allergy to paracetamol, caffeine or codeine
  • Asthma and acute/chronic respiratory insufficiency
  • Severe renal insufficiency (creatinine Cl<30 ml/min)
  • Pregnant/lactating women
  • Hepatic cirrhosis.
  • Refusal, incapacity or difficulties to consent or to communicate

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

1,500 participants in 3 patient groups

Paracétamol Group
Active Comparator group
Description:
In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracétamol Caféine Group) . In Paracetamol group , the patients will receive a pill containing 1000 mg of paracetamol 3 times a day for 7 days . Paracétamol 1000 mg : 1 pill \*3 / day
Treatment:
Drug: Paracetamol
Paracétamol Codéine Group
Active Comparator group
Description:
In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) . In Paracetamol codéine group , the patients will receive a pill containing an association of paracetamol and codéine ( 500mg / 30mg ) 3 times a day for 7 days . -Association of Paracétamol and Codéine ( 500mg / 30 mg) : 1 pill \*2 /day
Treatment:
Drug: Paracetamol Codeine
Paracétamol Caféine Group
Active Comparator group
Description:
In each study population, the patient will be assigned to one of three treatments (Paracetamol Group or Paracetamol Codéine Group or Paracetamol Caféine Group) . In Paracetamol caféine group , the patients will receive a pill containing an association of paracetamol and caféine ( 500mg / 65 mg ) 3 times a day for 7 days . -Association of Paracétamol and Caféine ( 500mg / 65 mg) : 1 pill \*3 /day
Treatment:
Drug: Paracetamol caféine

Trial contacts and locations

1

Loading...

Central trial contact

Nouira Semir; Nouira Semir

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems